SuperworthKaryopharm Therapeutics KPTI
- Market cap
- $11.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $146.6M
- +7% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Karyopharm Therapeutics trades at 0.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $146.6M over the last twelve months, up 7% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $36M−0% | $33.7M+1% | $33.1M−14% | $42.8M+14% | $38.8M+8% | $30.5M−10% | $30M−9% | $37.9M−11% | $44M+14% | $34.1M+12% | $35.1M+17% | $33.4M−12% | |
| Cost of revenue | $911K−7% | $1.5M−20% | $1.9M+42% | $1.5M+23% | $1.3M+43% | $1.3M−10% | $1.3M−32% | $1.1M−28% | $2.1M+63% | $1.5M+12% | $1.3M+3% | $1.1M+3% |
| Gross profit | $35.1M−0% | $32.3M+2% | $31.2M−16% | $41.3M+14% | $37.5M+7% | $29.2M−10% | $28.7M−8% | $36.9M−11% | $41.9M+12% | $32.6M+12% | $33.7M+17% | $32.3M−12% |
| R&D | $35.6M+13% | $39.4M+27% | $35.4M+10% | $38.4M+22% | $36.1M+2% | $33.3M−15% | $34.6M−2% | $32.8M−15% | $30.5M−16% | $27.7M−17% | $33.8M−2% | $29M−12% |
| SG&A | $30.8M−11% | $30.7M−11% | $29.5M−18% | $31.1M−10% | $27.6M−10% | $27.2M−11% | $27.4M−7% | $28.5M−8% | $26.6M−4% | $22.8M−16% | $26.7M−2% | $25.9M−9% |
| −$31.3M+1% | −$37.8M+12% | −$33.8M+9% | −$28.1M−5% | −$26.3M−16% | −$31.3M−17% | −$33.3M−2% | −$24.4M−13% | −$15.2M−42% | −$17.8M−43% | −$26.8M−20% | −$22.5M−8% | |
| Interest expense | $6.1M−1% | $6.2M+6% | $5.9M+2% | $8.9M+55% | $11.4M+88% | $11.2M+81% | $11M+87% | $11.2M+26% | $11M−3% | $12.6M+13% | $12.6M+14% | $13.1M+17% |
| Pre-tax income | −$34.5M−5% | −$41.7M+9% | −$37.3M+9% | $23.9M | −$32M−7% | −$30.9M−26% | −$23.4M−37% | −$37.2M | −$33.1M+3% | −$102.3M+231% | −$22.4M−4% | −$67M+80% |
| $12K−73% | $130K+78% | $71K+32% | $67K−47% | $28K+133% | −$109K | $36K−49% | $40K−40% | $34K+21% | −$67K−39% | $1K−97% | $0 | |
| Net income | −$34.5M−5% | −$41.8M+9% | −$37.4M+10% | $23.8M | −$32.1M−7% | −$30.8M−26% | −$23.5M−37% | −$37.3M | −$33.1M+3% | −$102.2M+232% | −$22.4M−5% | −$67M+80% |
| −$4.50−33% | −$5.40−16% | −$4.85+8% | −$2.97−32% | −$3.85−14% | −$3.67−32% | −$2.77−43% | −$4.32+46% | −$3.82−1% | −$5.71+56% | −$1.24−55% | −$2.32−46% | |
| 7.6M+43% | 7.7M+28% | 7.7M+2% | 10.3M+35% | 8.3M+9% | 8.4M+10% | 8.5M+10% | 8.6M−16% | 8.7M+4% | 17.9M+113% | 24.7M+192% | 28.9M+236% |
Gross profit: 22 periods, Q3 FY19 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 14 periods, Q1 FY12 to Q2 FY15: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Karyopharm Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KPTIKaryopharm Therapeutics | $11.7M | n/m | n/a | 0.1× | +7% | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Karyopharm Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #7of 496Healthcare stocks with the lowest price to sales ratio
- #3of 157Large drugmakers with the lowest price to sales ratio
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .